SciSparc Ltd. (SPRC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd., an Israeli biotech company, has entered into an exclusive patent license agreement with Polyrizon Ltd., granting the latter rights to develop and commercialize patented technologies and know-how for the diagnosis, prevention, and treatment of pain. The agreement confers Polyrizon a royalty-bearing, exclusive license, including the ability to sublicense, for the exploitation of these assets worldwide in the medical field. This strategic partnership promises to advance the development and potential commercialization of innovative pain treatments based on SciSparc’s proprietary technologies.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.